These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 36631870)

  • 21. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
    Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
    Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.
    Granbom E; Fernlund E; Sunnegårdh J; Lundell B; Naumburg E
    Acta Paediatr; 2014 Aug; 103(8):840-5. PubMed ID: 24724913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
    Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
    Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
    Gonzales T; Bergamasco A; Cristarella T; Goyer C; Wojdyla M; Oladapo A; Sawicky J; Yee J; Moride Y
    Am J Perinatol; 2024 May; 41(S 01):e1107-e1115. PubMed ID: 36452969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
    Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
    BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
    Ambrose CS; Chen X; Kumar VR
    Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.
    Cohen SA; Zanni R; Cohen A; Harrington M; VanVeldhuisen P; Boron ML;
    Pediatr Cardiol; 2008 Mar; 29(2):382-7. PubMed ID: 17926087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.
    Turti TV; Baibarina EN; Degtiareva EA; Keshishyan ES; Lobzin YV; Namazova-Вaranova LS; Prodeus AP; Gudkov KM; Kruglova AI; Schulz GA; Notario GF
    BMC Res Notes; 2012 Sep; 5():484. PubMed ID: 22943074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease.
    Walpert AS; Thomas ID; Lowe MC; Seckeler MD
    Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
    Oz-Alcalay L; Ashkenazi S; Glatman-Freedman A; Weisman-Demri S; Lowenthal A; Livni G
    Isr Med Assoc J; 2019 Feb; 21(2):110-115. PubMed ID: 30772962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
    Feltes TF; Cabalka AK; Meissner HC; Piazza FM; Carlin DA; Top FH; Connor EM; Sondheimer HM;
    J Pediatr; 2003 Oct; 143(4):532-40. PubMed ID: 14571236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.
    Simon A; Gehrmann S; Wagenpfeil G; Wagenpfeil S
    Eur J Pediatr; 2018 Jun; 177(6):903-911. PubMed ID: 29651734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The implications of airway anomalies on children with congenital heart disease and bronchiolitis.
    Wang PY; Tseng WC; Wu ET; Lu FL; Chen SJ; Chiu SN; Wu MH; Wang JK; Wang CC
    Pediatr Pulmonol; 2023 Apr; 58(4):1194-1200. PubMed ID: 36650613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Respiratory virus prophylaxis in congenital heart disease.
    Joshi M; Tulloh RM
    Future Cardiol; 2018 Sep; 14(5):417-425. PubMed ID: 29877720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study.
    Butt ML; Symington A; Janes M; Elliott L; Steele S; Paes BA
    Eur J Pediatr; 2011 Jul; 170(7):907-13. PubMed ID: 21174120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.